IP Library › Granted Patent US 12,514,832
Granted Patent B2
US 12,514,832 · App. 17/776,690 · Granted Jan 6, 2026

Methods for using low-dose colchicine after myocardial infarction

Inventors: Marie-Pierre Dubé (Montreal, CA); Jean-Claude Tardif (Montreal, CA)
Assignee: INSTITUT DE CARDIOLOGIE DE MONTREAL
A61K31/165A61P9/10C12Q1/6876C12Q1/6858C12Q2600/106C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,514,832
App. No.
17/776,690
Filed
May 13, 2022
Granted
Jan 6, 2026
Kind
B2
Examiner
WARD, PAUL V
Art Unit
1622
USPC
514/629
Abstract

The invention features methods of treating a patient after having a myocardial infarction including administering colchicine to a patient determined to have a genetic variant in the genome that is indicative of the patient benefiting from colchicine administration or not to have a genetic variant in the genome that is that is indicative of the patient suffering a gastrointestinal disorder following colchicine administration.

Claims (21)

1 . A method of treating a patient after having a myocardial infarction comprising administering colchicine to the patient determined to have a genetic variant in its genome that is indicative of the patient benefiting from colchicine administration, wherein the genetic variant comprises polymorphic site rs10811106 in the patient's SAXO1 gene on chromosome 9.

2 . A method of treating a patient after having a myocardial infarction comprising determining whether the patient has a genetic variant in its genome that is indicative of the patient benefiting from colchicine administration or does not have a genetic variant in the genome that is that is indicative of the patient suffering from a gastrointestinal disorder following colchicine administration, and administering colchicine to the patient determined to have a genetic variant in the genome that is indicative of the patient benefiting from colchicine administration or not to have a genetic variant in the genome that is that is indicative of the patient suffering a gastrointestinal disorder following colchicine administration, wherein the genetic variant in the genome that is indicative of the patient benefiting from colchicine administration comprises polymorphic site rs10811106 in the patient's SAXO1 gene on chromosome 9.

3 . A method of identifying a patient who would benefit from the administration of colchicine, comprising determining the genotype of the patient at one or more polymorphic sites in the subject's SAXO1 gene, wherein at least one polymorphic site is rs10811106.

4 . The method of claim 1 , wherein the myocardial infarction was within thirty days.

5 . The method of claim 4 , wherein the myocardial infarction was within 5, 10, 15, 20, or 25 days.

6 . The method of claim 1 , wherein percutaneous coronary intervention was performed for treating the patient's myocardial infarction.

7 . The method of claim 1 , wherein the patient was prescribed a medication.

8 . The method of claim 7 , wherein the medication is an antiplatelet agent or a statin.

9 . The method of claim 1 , wherein the patient is at a lower risk of an ischemic cardiovascular event.

10 . The method of claim 1 , wherein the colchicine is in the form of a tablet or capsule.

11 . The method of claim 1 , wherein the colchicine is administered at 0.3 to 0.7 mg.

12 . The method of claim 11 , wherein the colchicine is administered at 0.5 mg.

13 . The method of claim 1 , wherein colchicine is administered one, twice, or three times a day.

14 . The method of claim 13 , wherein 0.25 mg of colchicine is administered twice a day.

15 . The method of claim 1 , wherein the genotype at polymorphic site rs10811106 is C/C.

16 . The method of claim 1 , wherein the genome comprises a further genetic variant at a polymorphic site selected from the group consisting of rs10118790, rs28733572, rs1854156, and rs10963895.

17 . The method of claim 16 , wherein the genotype at polymorphic site rs10118790, rs28733572, rs1854156, and/or rs10963895 is G.

18 . The method of claim 1 , wherein the patient has two copies of the genetic variant indicative of the patient benefiting from colchicine administration.

19 . The method of claim 1 , wherein the patient is male.

20 . The method of claim 1 , wherein the colchicine administration reduces the likelihood of a further cardiovascular event in the patient.

21 . The method of claim 20 , wherein the further cardiovascular event is a myocardial infarction.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2023
From: DUBÉ, MARIE-PIERRE; TARDIF, JEAN-CLAUDE
To: INSTITUT DE CARDIOLOGIE DE MONTREAL
Reel/Frame 065808/0988 →
Continuity (2)
Provisional Application 62935751 · Nov 15, 2019
Related Publication 20220401388A1 · Dec 22, 2022
References Cited (39)
US 9744144B2 · Nidorf · 2017 [cited by applicant]
US 10105319B2 · Riel · 2018 [cited by applicant]
US 10130585B2 · Riel · 2018 [cited by applicant]
US 10206891B2 · Nidorf · 2019 [cited by applicant]
US 10265281B2 · Nidorf · 2019 [cited by applicant]
US 11400063B2 · Tardif · 2022 [cited by applicant]
US 20180318221A1 · Riel · 2018 [cited by applicant]
US 20190054028A1 · Riel · 2019 [cited by applicant]
US 20190117598A1 · Nidorf · 2019 [cited by applicant]
US 20210145773A1 · Tardif · 2021 [cited by applicant]
US 20220249409A1 · Tardif · 2022 [cited by applicant]
US 20230364040A1 · Tardif · 2023 [cited by applicant]
EP 3093351A1 · 2016 [cited by applicant]
WO WO2005027886A2 · 2005 [cited by applicant]
WO WO2007035953A2 · 2007 [cited by applicant]
WO WO2008132763A2 · 2008 [cited by applicant]
WO WO2014066944A1 · 2014 [cited by applicant]
Akodad et al., “Colchicine and myocardial infarction: A review,” Arch Cardiovasc Dis. 113(10):652-659 (Oct. 2020). [cited by applicant]
Akodad et al., “Interest of colchicine in the treatment of acute myocardial infarct responsible for heart failure in a mouse model,” Int J Cardiol. 240:347-353 (Aug. 2017). [cited by applicant]
Bouabdallaoui et al., “Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT),” Eur Heart J. 00:1-8 (Nov. 2020). [cited by applicant]
Deftereos et al., “Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study,” Circulation. 132(15):1395-403 (Oct. 2015). [cited by applicant]
Dubé et al., “Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT,” Circ Genom Precis Med. 14(2): e003183 (Apr. 2021) (7 pages). [cited by applicant]
Extended European Search Report for European Patent Application No. 20887173.1, dated Nov. 3, 2023 (10 pages). [cited by applicant]
Hennessy et al., “The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A pilot randomized placebo controlled trial of colchicine following acute myocardial infarction,” Am Heart J. 215:62-69 (Jun. 2019… [cited by applicant]
Montreal Heart Institute, “Colchicine Cardiovascular Outcomes Trial (COLCOT) (COLCOT)”, U.S. National Library of Medicine, ClinicalTrials.gov Identifier: NCT02551094, <https://clinicaltrials.gov/ct2/show/NCT02551094>, r… [cited by applicant]
Newby, “Inflammation as a Treatment Target after Acute Myocardial Infarction,” N Engl J Med. 381(26):2562-2563 (Dec. 2019). [cited by applicant]
Nidorf et al., “Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview,” Clin Ther. 41(1):41-48 (Jan. 2019). [cited by applicant]
Tucker et al., “Colchicine as a Novel Therapy for Suppressing Chemokine Production in Patients With an Acute Coronary Syndrome: A Pilot Study,” Clin Ther. 41(10):2172-2181 (Aug. 2019). [cited by applicant]
Vaidya et al., “Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome: A CT Coronary Angiography Study,” JACC Cardiovasc Imaging. 11(2 PT 2):305-316 (Feb. 2018). [cited by applicant]
Vaidya et al., “The Role of Colchicine in Acute Coronary Syndromes,” Clin Ther. 41(1):11-20 (Jan. 2019). [cited by applicant]
Fujisue et al., “Colchicine improves survival, left ventricular remodeling, and chronic cardiac function after acute myocardial infarction,” Circ J. 2017 81(8):1174-82 (2017). [cited by applicant]
International Preliminary Report on Patentability for International Patent Application No. PCT/CA2020/051559 issued May 17, 2022 (7 pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/CA2020/051559, mailed Jan. 15, 2021 (10 pages). [cited by applicant]
Nidorf et al., “Low-dose colchicine for secondary prevention of cardiovascular disease,” J Am Coll Cardiol. 61(4):404-410 (2013). [cited by applicant]
Rustemoglu et al., “MDR1 gene polymorphisms may be associated with Behçet's disease and its colchicum treatment response,” Gene. 505(2):333-9 (2012). [cited by applicant]
Tardif et al., “Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction,” N Engl J Med. 381(26):2497-2505 (Dec. 2019). [cited by applicant]
“History of Changes for Study: NCT02551094: Colchicine Cardiovascular Outcomes Trial (COLCOT),” U.S. National Library of Medicine, <https://clinicaltrials.gov/ct2/history/NCT02551094?A=8&B=8&C=merged#StudyPageTop>, date… [cited by applicant]
Tufan et al., “Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever,” J Rheumatol. 34(7): 1540-4 (2007). [cited by applicant]
Wendling, “The Earlier the Better for Colchicine Post-MI: COLCOT,” Medscape, <https://www.medscape.com/viewarticle/937041_print>, dated Sep. 8, 2020, retrieved on Oct. 5, 2022 (2 pages). [cited by applicant]